Quinazolinone-type compounds as CRTH2 antagonists

US8927559B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Robert G. Aslanian · Rockaway, US
• Christopher W. Boyce · Flemington, US
• Robert Mazzola · Stewartsville, US
• Brian McKittrick · New Vernon, US
• Kevin D. McCormick · Berkeley Heights, US
• Anandan Palani · Bound Brook, US
• Jun Qin · Edison, US
• Haiqun Tang · Montgomery, US
• Dong Xiao · Hackettstown, US
• Younong Yu · East Brunswick Township, US
• John P. Caldwell · Ringwood, US
• Elizabeth H. Kelley · Cambridge, US
• Hongjun Zhang · Waterloo, CA
• Phieng Siliphaivanh · Newton, US
• Rachel N. MacCoss · Brookline, US
• Joey L. Methot · Westwood, US
• Jolicia Polivina Gauuan · Schenectady, US
• Qin Jiang · Latham, US
• Andrew J. Leyhane · Latham, US
• Purakkattle Biju · Piscataway, US
• Li Dong · Lawrenceville, US
• Xianhai Huang · Hackettstown, US
• Ning Shao · Clark, US
• Wei Zhou · Scotch Plains, US
• Pawan Dhondi · Elizabeth, US
• Ashwin U. Rao · Avenel, US

Key dates

• Filing date: Oct 6, 2011
• Grant date: Jan 6, 2015
• Expiry date: Oct 6, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH2 receptor.